Allergan plc (NYSE:AGN) has received an average recommendation of “Hold” from the twenty-four research firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $175.18.
Several equities analysts have weighed in on the company. ValuEngine upgraded Allergan from a “strong sell” rating to a “sell” rating in a report on Tuesday, May 7th. Royal Bank of Canada cut their target price on Allergan from $165.00 to $140.00 and set a “sector perform” rating on the stock in a report on Wednesday, May 8th. UBS Group cut their target price on Allergan from $173.00 to $172.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Cantor Fitzgerald cut their target price on Allergan from $180.00 to $125.00 and set a “neutral” rating on the stock in a report on Wednesday, June 12th. Finally, Mizuho cut their target price on Allergan from $194.00 to $171.00 and set a “buy” rating on the stock in a report on Tuesday.
AGN traded up $32.86 during trading on Tuesday, reaching $162.43. 33,043,531 shares of the stock traded hands, compared to its average volume of 2,981,772. The stock has a market cap of $42.88 billion, a PE ratio of 9.73, a price-to-earnings-growth ratio of 1.21 and a beta of 1.39. Allergan has a fifty-two week low of $114.27 and a fifty-two week high of $197.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.60 and a current ratio of 0.71. The firm’s 50-day moving average price is $131.30.
Allergan (NYSE:AGN) last released its quarterly earnings data on Tuesday, May 7th. The company reported $3.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.55 by $0.24. The firm had revenue of $3.60 billion during the quarter, compared to analysts’ expectations of $3.55 billion. Allergan had a positive return on equity of 8.45% and a negative net margin of 45.94%. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same quarter last year, the firm earned $3.74 earnings per share. On average, equities research analysts expect that Allergan will post 16.67 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Tuesday, May 14th were paid a $0.74 dividend. The ex-dividend date was Monday, May 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.82%. Allergan’s payout ratio is presently 17.74%.
Institutional investors have recently bought and sold shares of the company. Wesbanco Bank Inc. increased its stake in shares of Allergan by 6.8% in the first quarter. Wesbanco Bank Inc. now owns 4,950 shares of the company’s stock worth $725,000 after purchasing an additional 316 shares during the period. Nomura Holdings Inc. increased its stake in shares of Allergan by 9.2% in the fourth quarter. Nomura Holdings Inc. now owns 30,522 shares of the company’s stock worth $4,074,000 after purchasing an additional 2,580 shares during the period. American Century Companies Inc. increased its stake in shares of Allergan by 21.1% in the fourth quarter. American Century Companies Inc. now owns 1,235,389 shares of the company’s stock worth $165,122,000 after purchasing an additional 214,955 shares during the period. Cetera Investment Advisers bought a new position in shares of Allergan in the first quarter worth about $233,000. Finally, Institute for Wealth Management LLC. bought a new position in shares of Allergan in the fourth quarter worth about $716,000. Institutional investors and hedge funds own 80.15% of the company’s stock.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Article: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.